Skip to main content

Tasmanian Devils Developing Resistance to Transmissible Cancer

The marsupials’ genomes show evidence of a rapid evolutionary response to selection imposed by devil facial tumor disease.

Written byAbby Olena, PhD
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00

WIKIMEDIA, KERESHDuring the last 20 years, a contagious cancer has decimated Tasmanian devil (Sarcophilus harrisii) populations. Cancer cells, which are spread by biting, grow deadly tumors on the faces and mouths of the aggressive marsupials. Because devil facial tumor disease (DFTD) has been observed in almost all known populations and is nearly 100 percent fatal, epidemiological models have suggested that the most long-infected populations are facing extinction.

“But they’re currently surviving,” said Andrew Storfer of Washington State University. Now, he and his colleagues have the start of an explanation as to why. In a study published today (August 30) in Nature Communications, Storfer and an international team of researchers reported genomic evidence to suggest that Tasmanian devils are evolving resistance to DFTD.

“It’s such an important finding,” said Beata Ujvari of Deakin University in Geelong, Australia, who did not participate in the work. “We suspected that the devils would evolve resistance to the disease,” she added. “It was really exciting to see that this hunch or hypothesis was actually correct.”

Storfer and colleagues scanned the genomes of 294 Tasmanian devils from three locations across the Australian island, examining tissue samples collected both ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • abby olena

    As a freelancer for The Scientist, Abby reports on new developments in life science for the website. She has a PhD from Vanderbilt University and got her start in science journalism as the Chicago Tribune’s AAAS Mass Media Fellow in 2013. Following a stint as an intern for The Scientist, Abby was a postdoc in science communication at Duke University, where she developed and taught courses to help scientists share their research. In addition to her work as a science journalist, she leads science writing and communication workshops and co-produces a conversational podcast. She is based in Alabama.  

    View Full Profile

Related Topics

Related articles background image
August 2026 Digest cover
August 2026

Epic Fail: Sea-Monkeys Sabotage Fieldwork

When Barry Hicks set out to photograph thrombolites, thousands of unexpected visitors photobombed his underwater images.

View this Issue
Overcoming Immunotherapy Resistance in Liver Cancer

Overcoming Immunotherapy Resistance in Liver Cancer

Axion Biosystems
Optimizing NGS Library Preparation for Reliable Sequencing Data

Optimizing NGS Library Preparation for Reliable Sequencing Data

Covaris
Using TCR Repertoire Sequencing to Advance Immunology Research

Using TCR Repertoire Sequencing to Advance Immunology Research

Miltenyi
Mapping Clonal Mosaicism in Aging Tissues

Mapping Clonal Mosaicism in Aging Tissues

Mission bio

Products

Sino Biological Logo

Sino Biological Launches SuperNuclease ® Pro with Free Trial Program

Sino Biological Logo

Sino Biological Launches Precisely Characterized Full-Length p-Tau217 Protein to Advance Next-Generation Alzheimer’s Biomarker Assay Development

A photo of a scientist placing the Resipher device on a 96-well plate.

Resipher: Continuous Live-Cell Mitochondrial Respiration Monitoring in 96-Well Plates

Lucid Scientific logo
Conceptual image of ice and frost.

The VAULT100 PRO: Inside the most advanced Stirling Ultracold ULT freezer ever built.

Stirling Ultracold logo